Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Novartis announced today that following a priority review, the US Food and Drug Administration has approved an update to the Gleevec (imatinib mesylate) tablets label to recommend 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the risk of recurrence inclusion criteria of the pivotal trial.

1 Feb 2012

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets, a new tablet combining the dipeptidyl peptidase-4 (DPP-4) inhibitor, linagliptin, and metformin.

31 Jan 2012

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

AMAG Pharmaceuticals, Inc. today announced the completion of patient enrollment in the second of the company's two phase III studies that comprise its global registrational program for Feraheme (ferumoxytol) in patients with iron-deficiency anemia (IDA) who are not candidates for oral iron, regardless of the underlying cause.

30 Jan 2012

Amorcyte commences enrollment in PreSERVE Phase 2 trial for acute myocardial infarction

Amorcyte, LLC, a NeoStem, Inc. company today announces the enrollment of the first patient in the Amorcyte PreSERVE Phase 2 trial for acute myocardial infarction.

25 Jan 2012

CHF associated with reduced patency after peripheral endovascular intervention

Congestive heart failure (CHF) is a highly prevalent comorbidity among patients with symptomatic peripheral arterial disease. The effect of CHF on the procedural success of endovascular treatment, however, remains unknown.

25 Jan 2012

Ikaria receives FDA orphan drug designation for use of iNO in PAH

Ikaria, Inc., a critical care company focused on developing and commercializing innovative therapies for critically ill patients, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the use of inhaled nitric oxide (iNO) with the INOpulse DS drug-delivery system as a combination product for pulmonary arterial hypertension.

23 Jan 2012

New book focuses on improving care for chronic diseases

Why does health care need to be redesigned? First - the current system is broken. It costs too much, and too often yields little value for patients and society. Second - it's fixable. The editors and authors of Great Health Care - Making It Happen are convinced of it.

20 Jan 2012

$Coexisting comorbidities increase treatment costs for older adults with hip fractures$

Coexisting comorbidities increase treatment costs for older adults with hip fractures

More than 250,000 hip fractures occur every year in the U.S., often resulting in hospitalization, surgery, nursing-home admission, long-term disability, and/or extended periods of rehabilitation. Independent existing medical conditions significantly increase the treatment cost and length of hospitalization for older adults who have sustained a hip fracture, according to a new study recently published in the Journal of Bone and Joint Surgery.

19 Jan 2012

Cardio3BioSciences raises €3.1M in non-dilutive funding

The Belgian biotechnology company, Cardio3BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, today announces it has secured a total of €3.1 million in non-dilutive funding from the Walloon Region and the European Commission's Seventh Framework Programme.

10 Jan 2012

CMS assigns permanent J-code for Savient's KRYSTEXXA to treat RCG

Savient Pharmaceuticals, Inc. today announced that a product-specific billing code, or permanent J-code, for KRYSTEXXA (pegloticase) became available on January 1, 2012.

7 Jan 2012

Genomic architecture predisposes supercentenarians to age-related diseases

The first-ever published whole-genome sequences of not just one, but two supercentenarians, aged more than 114 years, reveal that both unusual and common genetic phenomena contribute to the genetic background of extreme human longevity.

4 Jan 2012

BioLineRx commences BCM CE Mark registration trial for prevention of cardiac remodeling following AMI

BioLineRx, a biopharmaceutical development company, announced today the commencement of the PRESERVATION I clinical trial, a CE Mark registration trial of BCM (BL-1040), a novel medical device intended for the prevention of cardiac remodeling following an acute myocardial infarction (AMI).

4 Jan 2012

AirStrip's mobile patient monitoring applications receive CE Mark

AirStrip Technologies, Inc. has received CE Mark certification to market its innovative mobile patient monitoring applications in the European Community as well as other international territories outside Europe, company officials announced today.

3 Jan 2012

Oak Pharmaceuticals acquires three Lundbeck hospital-based injectables

Akorn, Inc., a niche generic pharmaceutical company, today announced that its wholly-owned subsidiary, Oak Pharmaceuticals, has acquired three off-patent, branded, hospital-based injectables from the US subsidiary of H. Lundbeck A/S.

23 Dec 2011

Despite improvements, disparities in diagnosis and treatment of depression remain

Despite improvements to diagnostic tools and therapies in the two last decades, significant disparities in the diagnosis and treatment of depression remain, according to Rutgers research published online by the American Journal of Public Health; print, February 2012.

21 Dec 2011

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB today announced the start of the EXXELERATE study which will evaluate the short- and long-term efficacy of Cimzia (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira(adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this study confirms previously announced plans.

21 Dec 2011

Heart-related deaths, other emergencies peak in holiday season

Steven Polevoi, MD, has seen it all. During his 23-year career, the medical director of the UCSF Emergency Department has done everything from treat traumatic injuries to deliver babies. While medical emergencies occur throughout the year, Polevoi sees the winter season and its related overindulgence as a pivotal time for preventing emergencies by listening to our bodies.

21 Dec 2011

Research roundup: Insurance coverage in the Great Recession; PCIP vs. CHIP

The researchers how physicians examined claims of lower back back pain and note that part of the "rising economic cost of this epidemic is the burgeoning use of indiscriminate imaging," specifically MRIs. Researchers divided patients into two groups and "the treating physician in group 1 patients was blinded to the MRI results, while the physician for group 2 patients decided on treatment after reviewing the MRI findings."

17 Dec 2011

Patients need less blood after surgery than is widely thought

Patients need less blood after surgery than is widely thought. A new study comparing two plans for giving blood transfusions following surgery showed no ill effects from postponing transfusion until patients develop signs of anemia or their hemoglobin concentration falls below 8 g/dL.

16 Dec 2011

Onyx announces data from three carfilzomib studies on RRMM

Onyx Pharmaceuticals, Inc. today announced summaries of three poster presentations of single-agent carfilzomib, a next generation proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma at the 53rd American Society of Hematology (ASH) Annual Meeting in San Diego, CA.

12 Dec 2011

Congestive Heart Failure News and Research

FDA extends Novartis' Gleevec label to three-year treatment in patients with KIT+ GIST after surgery

Boehringer Ingelheim, Lilly receive FDA approval for Jentadueto to treat type 2 diabetes

AMAG completes enrollment in Feraheme Phase III program for iron-deficiency anemia

Amorcyte commences enrollment in PreSERVE Phase 2 trial for acute myocardial infarction

CHF associated with reduced patency after peripheral endovascular intervention

Ikaria receives FDA orphan drug designation for use of iNO in PAH

New book focuses on improving care for chronic diseases

Coexisting comorbidities increase treatment costs for older adults with hip fractures

Cardio3BioSciences raises €3.1M in non-dilutive funding

CMS assigns permanent J-code for Savient's KRYSTEXXA to treat RCG

Genomic architecture predisposes supercentenarians to age-related diseases

BioLineRx commences BCM CE Mark registration trial for prevention of cardiac remodeling following AMI

AirStrip's mobile patient monitoring applications receive CE Mark

Oak Pharmaceuticals acquires three Lundbeck hospital-based injectables

Despite improvements, disparities in diagnosis and treatment of depression remain

UCB initiates EXXELERATE study in rheumatoid arthritis

Heart-related deaths, other emergencies peak in holiday season

Research roundup: Insurance coverage in the Great Recession; PCIP vs. CHIP

Patients need less blood after surgery than is widely thought

Onyx announces data from three carfilzomib studies on RRMM

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News